Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2003
12/31/2003WO2004000825A1 Novel compounds
12/31/2003WO2004000822A1 2-thioxothiazole derivative, method for preparing the same, and pharmaceutical composition containing the same
12/31/2003WO2004000819A1 New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives
12/31/2003WO2004000817A2 Benzimidazole compounds and their use as estrogen agonists/antagonists
12/31/2003WO2004000815A1 Acutumine and acutumine compounds, synthesis and use
12/31/2003WO2004000808A2 N-substituted piperidine derivatives as serotonin receptor agents
12/31/2003WO2004000807A1 Cannabinoid receptor agonists
12/31/2003WO2004000786A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
12/31/2003WO2004000785A2 Phenyloxyalkanonic acid derivatives as hppar activators
12/31/2003WO2004000781A2 Nitrooxyderivatives of cyclooxygenase-2 inhibitors
12/31/2003WO2004000762A2 Propionic acid derivatives and their use as hppars activators
12/31/2003WO2004000369A2 Method of magnetically manipulating a cell with magnetisable particles
12/31/2003WO2004000368A1 Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
12/31/2003WO2004000361A1 Metastable pharmaceutical compositions
12/31/2003WO2004000355A1 Combination treatment for depression and anxiety by nk1 and nk3 antagonists
12/31/2003WO2004000341A1 The pharmaceutical formulation of traditional chinese medicine for abstinence of drug and preparation method and use thereof
12/31/2003WO2004000333A1 Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives
12/31/2003WO2004000329A1 Prophylactic and therapeutic treatment of migraine and migraine-related diseases with macrolide and/or tetracycline compounds and/or gyrase inhibitors
12/31/2003WO2004000326A1 Combination therapy wherein a serotonin reuptake inhibitor is used
12/31/2003WO2004000325A1 Prostaglandin-containing preparation composition for nasal administration
12/31/2003WO2004000324A1 Pharmaceutical compositions for the treatment of diseases related to neurotrophines
12/31/2003WO2004000322A1 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
12/31/2003WO2004000321A1 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
12/31/2003WO2004000317A1 Pharmaceutical composition containing stabilised amorphous form of donepezil hydrochloride
12/31/2003WO2004000315A1 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators
12/31/2003WO2004000313A2 Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds
12/31/2003WO2004000312A2 Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
12/31/2003WO2004000303A1 Method for therapeutic modality on a patient organism during the cure of parkinson's disease
12/31/2003WO2004000300A1 Cyclooxygenase-2 inhibitors
12/31/2003WO2004000296A1 (2s)-2amino-a-{[2-(ethanimidoylamino) ethyl]thio}butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms
12/31/2003WO2004000294A1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
12/31/2003WO2004000292A1 Composition comprising stabilised choline ascorbate
12/31/2003WO2004000289A2 Preparations for the intranasal application of selected cgrp antagonists derived from amino acids and a method for their production
12/31/2003WO2004000275A1 Transdermal aerosol compositions
12/31/2003WO2004000237A2 Enhancing treatment of mdr cancer with adenosine a3 antagonists
12/31/2003WO2004000219A2 Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof
12/31/2003WO2004000205A2 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
12/31/2003WO2004000204A2 Labelled somatostatin analogs backbone cyclized through metal complexation
12/31/2003WO2004000197A2 Quick dissolve compositions and tablets based thereon
12/31/2003WO2004000042A2 Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress
12/31/2003WO2003088959A3 Treatment of parkinson's disease with cyclooxygenase-2 (cox 2) inhibitor(s)
12/31/2003WO2003082893A8 Theraputic methods and uses of sapogenins and their derivatives
12/31/2003WO2003080021A3 Formulation comprising buprenorphine
12/31/2003WO2003077832A3 Dexanabinol and dexanabinol analogs regulate inflammation related genes
12/31/2003WO2003076658A3 A susceptibility gene for late-onset idiopathic parkinson's disease
12/31/2003WO2003072704A3 RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
12/31/2003WO2003072055A3 Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors
12/31/2003WO2003068811A3 Cytotoxic t-cell epitopes from chlamydia
12/31/2003WO2003063758A3 Bicyclic cb2 cannabinoid receptor ligands
12/31/2003WO2003061573A3 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
12/31/2003WO2003060475A3 Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues
12/31/2003WO2003055912A3 Secreted proteins
12/31/2003WO2003020759A9 A caspase- 8 binding protein, its preparation and use
12/31/2003WO2003010286A9 Nucleic acids, polypeptides, and methods for modulating apoptosis
12/31/2003WO2002078747A9 Pregabalin lactose conjugates
12/31/2003WO2002070562A3 Nuclear hormone receptor ligand binding domain
12/31/2003WO2002064796A3 Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use
12/31/2003WO2002060378A3 Substituted aryl compounds as cyclooxygenase-2 selective inhibitors, compositions and methods of use
12/31/2003WO2002047708A3 Selective cox-2 inhibition from edible plant extracts
12/31/2003WO2002047706A3 Selective cox-2 inhibition from plant extracts
12/31/2003WO2002043578A3 Determination of risk and treatment of complications of prematurity
12/31/2003WO2002040671A3 Immunoglobulin superfamily proteins
12/31/2003WO2001006984A3 Small molecules useful in the treatment of inflammatory disease
12/31/2003CN1464881A New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
12/31/2003CN1464788A Pharmaceutical compositions for headache, migraine, nausea and emesis
12/31/2003CN1463968A 2-aryl-trisubstituted indole acetamide derivative and medicinal use thereof
12/31/2003CN1463967A Opioid receptor containing 3-pyrroline, process for preparing the same and use thereof
12/31/2003CN1463735A Drug rehabilitation oral liquid
12/31/2003CN1463697A Fluctin slow release tablet
12/31/2003CN1132837C 螺呋喃并吡啶芳烷基胺、其制法和中间体及其药物组合物和制药用途 Spiro furopyridine arylalkylamines, their preparation and intermediates and pharmaceutical compositions thereof and pharmaceutical use
12/31/2003CN1132820C Crystal modified body of medicine
12/31/2003CN1132614C Medicine for treating hemicrania and its preparing process
12/31/2003CN1132593C Mixture of white pepper and borneol and its application
12/31/2003CN1132581C Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitiors
12/31/2003CA2491803A1 Novel kcnq polypeptides, modulators thereof, and their uses in the treatment of mental disorders
12/31/2003CA2491214A1 Acutumine and acutumine compounds, synthesis and use
12/31/2003CA2491210A1 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
12/31/2003CA2491209A1 Nitrooxyderivatives of cyclooxygenase-2 inhibitors
12/31/2003CA2491196A1 Materials and methods for inductions of immune tolerance
12/31/2003CA2490684A1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
12/31/2003CA2490526A1 Hetero-bicyclic compounds
12/31/2003CA2490397A1 N-substituted piperidine derivatives as serotonin receptor agents
12/31/2003CA2490392A1 Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
12/31/2003CA2490365A1 Quick dissolve compositions and tablets based thereon
12/31/2003CA2490325A1 Transdermal aerosol compositions
12/31/2003CA2490121A1 Modified phospholipids
12/31/2003CA2490100A1 Pharmaceutical formulation for use in treating drug withdrawal and preparation method
12/31/2003CA2490082A1 Quinuclidine derivatives and pharmaceutical compositions containing the same
12/31/2003CA2490057A1 Metastable pharmaceutical compositions
12/31/2003CA2489911A1 Pasteurisation process for microbial cells and microbial oil
12/31/2003CA2489905A1 Osteopontin, oligodendrocytes and myelination
12/31/2003CA2489561A1 Compounds that bind to the interferon-gamma, preparation method thereof and medicaments containing same
12/31/2003CA2489359A1 Propionic acid derivatives and their use as hppars activators
12/31/2003CA2489024A1 Use of pp2a phosphatase modulators in the treatment of mental disorders
12/31/2003CA2488311A1 Combination treatment for depression and anxiety by nk1 and nk3 antagonists
12/31/2003CA2487909A1 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators
12/31/2003CA2487718A1 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors
12/31/2003CA2487716A1 Pharmaceutical composition for the intranasal application containing selected cgrp antagonists derived from amino acids and process for preparing them
12/31/2003CA2487541A1 Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
12/31/2003CA2487346A1 Cannabinoid receptor agonists
1 ... 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 ... 1833